Staphylococcus aureus vaccine for orthopedic patients: an economic model and analysis
- PMID: 20064479
- PMCID: PMC2833350
- DOI: 10.1016/j.vaccine.2009.12.075
Staphylococcus aureus vaccine for orthopedic patients: an economic model and analysis
Abstract
To evaluate the potential economic value of a Staphylococcus aureus vaccine for pre-operative orthopedic surgery patients, we developed an economic computer simulation model. At MRSA colonization rates as low as 1%, a $50 vaccine was cost-effective [<or=$50,000 per quality-adjusted life year (QALY) saved] at vaccine efficacy >or=30%, and a $100 vaccine at vaccine efficacy >or=70%. High MRSA prevalence (>or=25%) could justify a vaccine price as high as $1000. Our results suggest that a S. aureus vaccine for the pre-operative orthopedic population would be very cost-effective over a wide range of MRSA prevalence and vaccine efficacies and costs.
Figures
References
-
- Walley G. Methicillin resistant Staphylococcus Aureus (MRSA) is not always caught on the orthopaedic ward. Acta Orthop Belg. 2009;75:245–51. ea. - PubMed
-
- Kato D, Maezawa K, Yonezawa I, Iwase Y, Ikeda H, Nozawa M, et al. Randomized prospective study on prophylactic antibiotics in clean orthopedic surgery in one ward for 1 year. J Orthop Sci. 2006 Jan;11(1):20–7. - PubMed
-
- Roche SJ, Fitzgerald D, O’Rourke A, McCabe JP. Methicillin-resistant Staphylococcus aureus in an Irish orthopaedic centre: a five-year analysis. J Bone Joint Surg Br. 2006 Jun;88(6):807–11. - PubMed
-
- Witte W, Braulke C, Heuck D, Cuny C. Analysis of nosocomial outbreaks with multiply and methicillin-resistant Staphylococcus aureus (MRSA) in Germany: implications for hospital hygiene. Infection. 1994;22(Suppl 2):S128–34. - PubMed
-
- Peacock JE, Jr., Marsik FJ, Wenzel RP. Methicillin-resistant Staphylococcus aureus: introduction and spread within a hospital. Ann Intern Med. 1980 Oct;93(4):526–32. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
